Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

A Michlmayr; T Bachleitner-Hofmann; S Baumann; M Marchetti-Deschmann; I Rech-Weichselbraun; C Burghuber; U Pluschnig; R Bartsch; A Graf; Richard Greil; G Allmaier; G Steger; M Gnant; M Bergmann; R Oehler

doi:10.1038/sj.bjc.6605909

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

A Michlmayr
, T Bachleitner-Hofmann
, S Baumann
, M Marchetti-Deschmann
, I Rech-Weichselbraun
, C Burghuber
, U Pluschnig
, R Bartsch
, A Graf
, Richard Greil (Co-Autor/-in)
, G Allmaier
, G Steger
, M Gnant
, M Bergmann
, R Oehler

Universitätsklinik für Innere Medizin 3 - Hämatologie, internistische Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

32 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	1201-1208
Fachzeitschrift	BRITISH JOURNAL OF CANCER
Jahrgang	103
Ausgabenummer	8
DOIs	https://doi.org/10.1038/sj.bjc.6605909
Publikationsstatus	Veröffentlicht - 2010

Zugriff auf Dokument

10.1038/sj.bjc.6605909

Dieses zitieren

Michlmayr, A., Bachleitner-Hofmann, T., Baumann, S., Marchetti-Deschmann, M., Rech-Weichselbraun, I., Burghuber, C., Pluschnig, U., Bartsch, R., Graf, A., Greil, R., Allmaier, G., Steger, G., Gnant, M., Bergmann, M., & Oehler, R. (2010). Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. BRITISH JOURNAL OF CANCER , 103(8), 1201-1208. https://doi.org/10.1038/sj.bjc.6605909

Michlmayr, A ; Bachleitner-Hofmann, T ; Baumann, S et al. / Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. in: BRITISH JOURNAL OF CANCER 2010 ; Jahrgang 103, Nr. 8. S. 1201-1208.

@article{148ab9fcfeaa481da64f9e263669c20a,

title = "Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.",

keywords = "PROTEIN IDENTIFICATION, PROTEOMIC ANALYSIS, MASS-SPECTROMETRY, SERUM BIOMARKERS, TUMOR-CELLS, IN-VIVO, CHEMOTHERAPY, DOXORUBICIN, VALIDATION, DISCOVERY",

author = "A Michlmayr and T Bachleitner-Hofmann and S Baumann and M Marchetti-Deschmann and I Rech-Weichselbraun and C Burghuber and U Pluschnig and R Bartsch and A Graf and Richard Greil and G Allmaier and G Steger and M Gnant and M Bergmann and R Oehler",

note = "3rd Medical Department, Private Medical University Hospital Salzburg, A-5020, Salzburg, Austria",

year = "2010",

doi = "10.1038/sj.bjc.6605909",

language = "English",

volume = "103",

pages = "1201--1208",

journal = "BRITISH JOURNAL OF CANCER ",

issn = "0007-0920",

publisher = "Springer Nature",

number = "8",

}

Michlmayr, A, Bachleitner-Hofmann, T, Baumann, S, Marchetti-Deschmann, M, Rech-Weichselbraun, I, Burghuber, C, Pluschnig, U, Bartsch, R, Graf, A, Greil, R, Allmaier, G, Steger, G, Gnant, M, Bergmann, M & Oehler, R 2010, 'Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.', BRITISH JOURNAL OF CANCER , Jg. 103, Nr. 8, S. 1201-1208. https://doi.org/10.1038/sj.bjc.6605909

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. / Michlmayr, A; Bachleitner-Hofmann, T; Baumann, S et al.
in: BRITISH JOURNAL OF CANCER , Jahrgang 103, Nr. 8, 2010, S. 1201-1208.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

TY - JOUR

T1 - Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

AU - Michlmayr, A

AU - Bachleitner-Hofmann, T

AU - Baumann, S

AU - Marchetti-Deschmann, M

AU - Rech-Weichselbraun, I

AU - Burghuber, C

AU - Pluschnig, U

AU - Bartsch, R

AU - Graf, A

AU - Greil, Richard

AU - Allmaier, G

AU - Steger, G

AU - Gnant, M

AU - Bergmann, M

AU - Oehler, R

N1 - 3rd Medical Department, Private Medical University Hospital Salzburg, A-5020, Salzburg, Austria

PY - 2010

Y1 - 2010

KW - PROTEIN IDENTIFICATION

KW - PROTEOMIC ANALYSIS

KW - MASS-SPECTROMETRY

KW - SERUM BIOMARKERS

KW - TUMOR-CELLS

KW - IN-VIVO

KW - CHEMOTHERAPY

KW - DOXORUBICIN

KW - VALIDATION

KW - DISCOVERY

U2 - 10.1038/sj.bjc.6605909

DO - 10.1038/sj.bjc.6605909

M3 - Original Article

C2 - 20877360

SN - 0007-0920

VL - 103

SP - 1201

EP - 1208

JO - BRITISH JOURNAL OF CANCER

JF - BRITISH JOURNAL OF CANCER

IS - 8

ER -

Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C et al. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. BRITISH JOURNAL OF CANCER . 2010;103(8):1201-1208. doi: 10.1038/sj.bjc.6605909